23 décembre 2020 Ce document résume les recommandations de l'OMS concernant l'utilisation rationnelle des équipements de protection individuelle (EPI) dans les établissements de soins de santé et les stratégies temporaires en cas de pénurie aiguë d'approvisionnement. Ce document contient ég...alement 2 sections en annexe qui décrivent les recommandations actualisées d'utilisation des EPI pour les travailleurs de la santé en fonction du scénario de transmission, du milieu et de l'activité dans le contexte de COVID-19 (annexe 1), et des considérations actualisées pour la décontamination ou le retraitement des EPI (annexe 2). Ce guide est destiné aux autorités de santé publique, aux organisations et aux personnes de référence impliquées dans les décisions concernant la distribution, la gestion et l'utilisation des EPI par les travailleurs de la santé.
more
The WHO Pharmaceuticals Newsletter provides you with the latest information on the safety of medicinal products and regulatory actions taken by authorities around the world.
In addition, this edition includes summary and recommendations from the virtual meeting of the members of the WHO Programme f...or International Drug Monitoring (PIDM) and other partners, which was held on 20 October 2022.
more
This SOP guides AFRO management, incident responders, and the Support for Health Operations Centre (SHOC) on managing public health events, detailing processes from event detection and risk assessment to resource mobilization and communication between country offices, the Regional Office, and WHO He...adquarters
more
Access to controlled medicines. 3rd edition
the Principles for Dose-Sharing provide a framework for higher-income economies to make additional volumes secured via bilateral deals available through the Facility primarily to AMC participants, on an equitable basis. These principles outline that such doses must be safe and effective, available a...s early as possible and should be available in substantive volumes as early as possible in 2021 to enable rapid and flexible deployment by the Facility – supporting the overall goal of equitable access.
18 Dec 2020
more
This presentation presents the issues we confront in deciding how to communicate to the public that COVID-19 vaccine recommendations reflect the state of scientific knowledge.
Will COVID-19 vaccines be safe? Will all the COVID-19 candidate vaccines be successful? What are the different phases a vaccine must go through to be approved? This document provides responses to the most frequently asked questions about candidate vaccines and access to COVID-19 vaccination.
IN THE AMOUNT OF SDR 21.8 MILLION (US$30 MILLION EQUIVALENT) WITH AN ADDITIONAL GRANT FROM THE GLOBAL FINANCING FACILITY (GFF) IN THE AMOUNT OF US$ 10 MILLION TO THE DEMOCRATIC REPUBLIC OF CONGO FOR A HUMAN DEVELOPMENT SYSTEMS STRENGTHENING PROJECT
Project Paper to provide an additional grant for: Human Development Systems Strengthening Project (HDSSP)(P145965, H9360)
11 august 2022, updated version
On the 9 February 2021, Africa CDC convened a special session of the Africa Task Force for COVID-19 to review existing data and evidence and recommend
Manufacturers:
SK Bioscience Co. Ltd. [COVID-19 Vaccine (ChAdOx1-S [recombinant])]
Serum Institute of India Pvt. Ltd. [COVISHIELD™, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)]
Efficacy shown in clinical trials in participants who received the full series of vaccine (2 doses) ir...respective of interval between the doses was 63.1%, based on a median follow-up of 80 days, but tended to be higher when this interval was longer. The data reviewed at this time support the conclusion that the known and potential benefits of ChAdOx1-S/nCoV-19 [recombinant] vaccine outweigh the known and potential risks.
more
The COVID-19 Vaccine (Whole Virion Inactivated) BBV152, COVAXIN® vaccine explainer includes key information on the vaccine specific requirements.